UNSPSC 51402207: Etifoxine

This classification denotes an anxiolytic with the molecular formula C17H17ClN2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier X24X82MX4X, chemically known as 6-chloro-2-ethylamino-4-methyl-4-phenyl-4h-3,1-benzoxazine but more generally known as etifoxine, which bears U.S. National Institutes of Health Compound Identifier 30768. European Medicines Agency schedules Etifoxine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07302MIG.

UNSPSC 51402207 Etifoxine, a Commodity code, shows limited recent activity directly aligned with the code's nominal pharmaceutical scope. The three recent state and local opportunities posted under this code involve naloxone procurement, direct-to-manufacturer pharmacy initiatives, and generic multi-source pharmaceutical supply agreements — none of which center on etifoxine specifically. The code's recent solicitations reflect broader pharmaceutical supply and opioid-response product procurement across county health departments, state health and human services commissions, and cooperative purchasing alliances, though the etifoxine code designation appears misaligned with the actual products being solicited in each case.

Issuing bodies include Seminole County, Florida (county health department), the Texas Health and Human Services Commission (state agency), and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration. The recent opportunities span Florida, Texas, and Minnesota. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. The Texas HHS Commission posted an RFI (HHS0017013, due April 3, 2026) to explore vendor capabilities for a direct-to-manufacturer prescription program. MMCAP issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with contract effectiveness set for July 1, 2026. The code shows minimal recent targeted demand for etifoxine itself; state and local procurement under this designation is currently driven by opioid-response products, pharmacy benefit management modernization, and commodity-level pharmaceutical supply aggregation rather than etifoxine procurement.